



Carbon Reduction Plan

Supplier name: Beaumont Pharma Ltd

Publication date: 26.03.26

Commitment to achieving Net Zero

Beaumont Pharma Ltd is committed to achieving Net Zero emissions by 2040

Baseline Emissions Footprint

The baseline emissions below are the reference point against which our future emissions reduction will be measured.

Baseline Emissions Year 2023

Scope 1

Beaumont Pharma Ltd is a virtual distribution company which does not own any assets directly involved in generation of GHG emissions. Beaumont Pharma does not manufacture products. All employees and contractors work remotely from their homes and our supply chain is managed entirely on an out-sourced basis. Emissions in this Scope are NIL

Scope 2

Total estimated emissions from purchase of electricity and gas for the home-based office is **13,340kgCO₂e**

Scope 3

- Business travel is estimated at 2,000 miles per year, equivalent to **616kgCO₂e**
- Employee commuting is zero
- Waste generated in operations is zero
- Upstream emissions from transportation and distribution are estimated from data provided by our partner organisations and are **20,550kgCO₂e**
- Downstream transportation and distribution emissions attributable to Beaumont Pharma Ltd by our pre-wholesale partner Alloga were **6,367 kgCO₂e** in 2023

Total emissions for baseline year 2023

40,873kgCO₂e

Current Emissions Reporting for 2025

Scope 1

Beaumont Pharma Ltd is a virtual distribution company which does not own any assets directly involved in generation of GHG emissions. Beaumont Pharma does not manufacture products. All employees and contractors work remotely from their homes and our supply chain is managed entirely on an out-sourced basis. Emissions in this Scope are NIL

Scope 2

Our current estimate for Beaumont Pharma direct emissions is **11,506kgCO₂e**. We estimate that the projects implemented in 2024 and 2025 have achieved a c.13% reduction in scope 2 emissions versus the 2023 baseline.

Scope 3

- Business travel for 2025 was estimated at 1,550 miles per year, equivalent to **477kgCO₂e**
- Employee commuting is zero
- Waste generated in operations is zero
- We are heavily linked to our partner organisations for Scope 3 emissions resulting from the distribution of our products. Upstream emissions from transportation and distribution are estimated from data provided by our partner organisations for 2023 these were **20,550kgCO₂e**. We do not currently have updated figures from all of our outsourcing partners for 2025 but we continue to request this.
- We rely primarily on Alloga for downstream distribution in the UK and Alloga have now reduced their own Scope 2 emissions to zero through the use of entirely renewable electricity sources. Downstream transportation and distribution emissions estimated as attributable to Beaumont Pharma Ltd were **3,639 kgCO₂e** for 2025. This represents a reduction of 42% compared with baseline year 2023 resulting from the switch to HVO fuel.

Total emissions for 2025 (estimated)

36,172 kgCO₂e – this represents a 11.5% reduction overall compared with 2023.

Emissions reduction targets

With 2023 as baseline year, 2025 was our second full year of implementing projects to reduce our carbon footprint during which we continued to use only LED lighting through the house and office to reduce Scope 2 emissions. We use our home as our place of work and have allocated 50% of our total energy usage to Beaumont Pharma Ltd. In order to continue our progress towards achieving Net Zero by 2040, we have set a target to make a further 5% reduction in Scope 3 emissions during 2026. Confirmation from our upstream distribution partners of switches to renewable energy sources and HVO would make a significant indirect reduction to the emissions attributable to Beaumont Pharma Ltd.

We project that carbon emissions will decrease over the next four years to 24,250kgCO₂e by 2028. This is a reduction of 30%.

Carbon Reduction Projects

The following environmental management measures and projects are in progress in year 2025:

- Use of public transport where possible, reducing consumption of petrol
- Maximising recycling of all waste
- Minimising single use plastics
- Beaumont Pharma Ltd continues to encourage our business partners to provide evidence of their projects and initiatives to reduce their carbon footprints

These measures will be in effect when performing the contract throughout the current year.

Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

Signed on behalf of the Supplier:



.....

Dr Jane Sharples⁴
Managing Director
Beaumont Pharma Ltd
Date: 26.03.26

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>